News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
486,504 Results
Type
Article (8039)
Company Profile (142)
Press Release (478322)
Multimedia
Podcasts (4)
Webinars (6)
Section
Business (166751)
Career Advice (302)
Deals (25739)
Drug Delivery (7)
Drug Development (52888)
Employer Resources (14)
FDA (9761)
Job Trends (8572)
News (238210)
Policy (17893)
Tag
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (6)
2027 Biotech Beach Elite (1)
2027 Biotech Beach Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (2)
2027 Pharm Country Digital (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (492)
Accelerated approval (26)
ADA (18)
Adcomms (1)
Allergies (98)
Alliances (33158)
ALS (114)
Alzheimer's disease (990)
Antibody-drug conjugate (ADC) (290)
Approvals (10433)
Artificial intelligence (341)
ASCO (159)
Autoimmune disease (226)
Automation (30)
Bankruptcy (263)
Belgium (3)
Best Places to Work (6963)
BIO (36)
Biologics (10)
BIOSECURE Act (1)
Biosimilars (118)
BioSpace Insights (17)
Biotechnology (90)
Bispecific (2)
Bladder cancer (140)
Brain cancer (33)
Breast cancer (522)
Cancer (3812)
Cardiovascular disease (228)
Career advice (245)
Career pathing (1)
CAR-T (181)
CDC (1)
CDMO (21)
Celiac Disease (1)
Cell therapy (495)
Cervical cancer (35)
Clinical research (48152)
Collaboration (1296)
Commercialization (3)
Compensation (1544)
Complete response letters (35)
COVID-19 (767)
CRISPR (64)
C-suite (818)
Cystic fibrosis (87)
Data (5955)
Denatured (4)
Depression (107)
Dermatology (74)
Diabetes (363)
Diagnostics (4227)
Digital health (39)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (161)
Drug pricing (7)
Drug shortages (2)
Duchenne muscular dystrophy (168)
Earnings (73766)
Editorial (1)
Employer branding (2)
Employer resources (14)
Events (88219)
Executive appointments (721)
FDA (12549)
Fibrodysplasia Ossificans Progressiva (10)
Friedreich's ataxia (19)
Frontotemporal dementia (24)
Funding (967)
Gene editing (126)
Generative AI (11)
Gene therapy (338)
GLP-1 (297)
Government (949)
Grass and pollen (2)
Guidances (281)
Healthcare (9369)
Hematology (94)
HIV (55)
Huntington's disease (23)
IgA nephropathy (70)
Immunology and inflammation (108)
Immuno-oncology (62)
Indications (168)
Infectious disease (960)
Inflammatory bowel disease (131)
Inflation Reduction Act (4)
Influenza (85)
Intellectual property (266)
Interviews (41)
IPO (12389)
IRA (2)
Job creations (1968)
Job search strategy (235)
JPM (1)
Kidney cancer (17)
Kidney disease (46)
Layoffs (59)
Legal (5195)
Licensing (22)
Liver cancer (46)
Longevity (20)
Lung cancer (552)
Lymphoma (261)
Machine learning (29)
Management (3)
Manufacturing (586)
Marketing (8)
MASH (118)
Medical affairs (2)
Medical device (8689)
Medtech (8851)
Mergers & acquisitions (14421)
Metabolic disorders (738)
mRNA (69)
Multiple sclerosis (107)
NASH (4)
Neurodegenerative disease (229)
Neuropsychiatric disorders (40)
Neuroscience (1888)
NextGen: Class of 2026 (3155)
Non-profit (843)
Obesity (235)
Opinion (11)
Ovarian cancer (164)
Pain (179)
Pancreatic cancer (209)
Parkinson's disease (208)
Partnered (12)
Patents (508)
Patient recruitment (534)
Patient selection (11)
Peanut (32)
People (41410)
Peptides (3)
Pharmaceutical (30)
Pharmacy benefit managers (9)
Phase 1 (15551)
Phase 2 (21506)
Phase 3 (14521)
Pipeline (7893)
Policy (18)
Postmarket research (1570)
Preclinical (6564)
Press Release (34)
Prostate cancer (193)
Psychedelics (9)
Radiopharmaceuticals (196)
Rare diseases (598)
Real estate (3024)
Recruiting (6)
Regenerative medicine (5)
Regulatory (15038)
Reports (23)
Research institute (586)
Resumes & cover letters (45)
Rett syndrome (43)
RNA editing (6)
RSV (48)
Schizophrenia (104)
Series A (167)
Series B (124)
Service/supplier (5)
Sickle cell disease (63)
Spinal muscular atrophy (91)
Sponsored (5)
Startups (2020)
Stomach cancer (3)
Substance use disorders (16)
Supply chain (51)
Vaccines (336)
Venture capital (17)
Weight loss (75)
Women's health (91)
Date
Today (95)
Last 7 days (315)
Last 30 days (1554)
Last 365 days (19089)
2026 (14105)
2025 (19252)
2024 (22988)
2023 (26539)
2022 (34588)
2021 (37170)
2020 (33475)
2019 (23241)
2018 (17471)
2017 (18768)
2016 (17920)
2015 (24251)
2014 (21679)
2013 (18135)
2012 (20221)
2011 (20441)
2010 (20332)
Location
Africa (228)
Alabama (80)
Alaska (2)
Arizona (313)
Arkansas (10)
Asia (17970)
Australia (2095)
California (12480)
Canada (3275)
China (556)
Colorado (507)
Connecticut (434)
Delaware (218)
Europe (24660)
Florida (1875)
Georgia (395)
Hawaii (3)
Idaho (46)
Illinois (739)
India (54)
Indiana (326)
Iowa (16)
Japan (433)
Kansas (104)
Kentucky (32)
Louisiana (27)
Maine (26)
Maryland (1239)
Massachusetts (8165)
Michigan (315)
Minnesota (575)
Mississippi (4)
Missouri (83)
Montana (20)
Nebraska (11)
Nevada (124)
New Hampshire (60)
New Jersey (2734)
New Mexico (12)
New York (2927)
North Carolina (1323)
North Dakota (4)
Northern California (6278)
Ohio (298)
Oklahoma (14)
Oregon (16)
Pennsylvania (2320)
Puerto Rico (24)
Rhode Island (30)
South America (403)
South Carolina (78)
South Dakota (1)
Southern California (5204)
Tennessee (125)
Texas (2040)
United States (40438)
Utah (377)
Vermont (1)
Virginia (159)
Washington D.C. (39)
Washington State (963)
West Virginia (1)
Wisconsin (78)
Wyoming (1)
486,504 Results for "advaxis inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Advaxis and Ayala Pharmaceuticals Complete Merger
Advaxis, Inc. (OTCQX: ADXS) today announced the completion of a previously announced merger with Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA).
January 19, 2023
·
4 min read
Deals
Ayala Pharmaceuticals and Advaxis Enter into Merger Agreement
Ayala Pharmaceuticals, Inc. and Advaxis, Inc. announced that they have entered into a definitive merger agreement.
October 19, 2022
·
13 min read
Deals
Advaxis and Ayala Pharmaceuticals Enter into Merger Agreement
Ayala Pharmaceuticals, Inc. and Advaxis, Inc. announced that they have entered into a definitive merger agreement.
October 19, 2022
·
13 min read
Press Releases
OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceuticals
April 9, 2025
·
6 min read
Pharm Country
Advaxis, Inc. Announces 1-for-80 Reverse Stock Split
Advaxis, Inc. announced that it has filed a Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Company to implement a one-for-80 reverse split of its issued and outstanding common stock.
June 3, 2022
·
5 min read
Pharm Country
Advaxis, Inc. Issues Letter to Stockholders - Nov 19, 2021
Advaxis, Inc., a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, issued the following statement to stockholders.
November 19, 2021
·
10 min read
Deals
OTC Markets Group Welcomes Advaxis, Inc. to OTCQX
OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for over 11,000 U.S. and global securities, today announced Advaxis, Inc. (OTCQX: ADXS), a clinical-stage biotechnology company, has qualified to trade on the OTCQX® Best Market.
December 23, 2021
·
2 min read
Drug Development
Advaxis Updates on the Phase 1 Clinical Trial of ADXS-504 for the Treatment of Early Prostate Cancer
Advaxis, Inc. today announced an update on the Phase 1 clinical study evaluating ADXS-504, the company’s off-the-shelf neoantigen drug candidate, in patients with biochemically recurrent (early) prostate cancer that is being conducted at Columbia University Irving Medical Center.
January 12, 2023
·
5 min read
Deals
Advaxis and Ayala Merge to Hone In on Desmoid Tumors, Prostate Cancer
Advaxis and Ayala Pharmaceuticals entered a reverse merger deal to focus on two clinical-stage cancer therapies: AL102 for desmoid tumors and ADXS-504 for prostate cancer.
October 19, 2022
·
2 min read
·
Mark Terry
Business
Advaxis Reports Third Quarter Ended July 31, 2022 Financial Results and Provides a Business Update
Advaxis, Inc. (OTCQX: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announces its financial results for the third quarter ended July 31, 2022 and provides a business update.
September 12, 2022
·
6 min read
1 of 48,651
Next
